Welcome to our dedicated page for COVALON TECHS news (Ticker: CVALF), a resource for investors and traders seeking the latest updates and insights on COVALON TECHS stock.
Covalon Technologies Ltd. reports company developments across advanced medical technologies for vascular access, infection prevention, wound care, and surgical consumables. Recurring updates describe clinical education, healthcare-conference activity, and product use around contamination of intravenous connections, healthcare-associated infection risk, skin integrity, and patient-care workflows.
Covalon news also includes fiscal results, management discussion and analysis availability, shareholder meeting matters, director compensation through deferred share units, and amendments to governance documents and incentive plans. Product-specific coverage includes solutions such as CovaClear IV Cover dressings and VALGuard Vascular Access Line Guard.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has released a statement addressing the recent tariffs announced by President Trump on Canadian imports. The company maintains manufacturing and commercial operations on both sides of the US-Canada border and has flexibility to adjust manufacturing processes and locations to potentially mitigate negative financial impacts.
The company benefits from foreign exchange rates, with most revenues in US Dollars and costs in Canadian Dollars. The current exchange rate is 1.45 CAD/USD, compared to 1.35 a year ago. Covalon had a successful 2024 fiscal year and was ranked as the top medical device company and #4 overall on the OTCQX's Best 50 Companies list, based on one-year total return and average daily dollar volume growth.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has been named one of the 2025 OTCQX Best 50 companies, ranking #4 overall and emerging as the top Medical Device company. The recognition is based on total return and growth in average daily dollar volume throughout 2024.
The company achieved a remarkable 207% total return in 2024, significantly outperforming the Best 50 median of 74%. The OTCQX Best 50 companies collectively traded over $5.8 billion in dollar volume during 2024, with representatives from the United States, Canada, the United Kingdom, Australia, and Turkey.
CEO Brent Ashton highlighted that this achievement demonstrates Covalon's growing international investor following and recognition of its long-term potential. The company reports accelerated interest from both sophisticated microcap communities and institutional healthcare investors.
Covalon Technologies reported strong financial results for Q4 and fiscal year 2024. Q4 revenue increased 29% to $8.9 million, with full-year revenue up 17% to $31.2 million. Product revenue grew significantly, rising 35% in Q4 and 30% for the full year, driven by stronger customer demand for collagen dressings and expanded product offerings in US hospitals.
The company demonstrated improved profitability with Q4 gross profit of $5.3 million (82.8% growth) and full-year gross profit of $18.9 million (31.3% growth). Q4 Adjusted EBITDA reached $1.1 million, a $2.9 million improvement over Q4 FY'23. Earnings per share for Q4 was $0.02 and $0.11 for the full year, marking significant improvements from previous periods.
Operating expenses decreased to $4.7 million in Q4 from $5.8 million, primarily due to restructuring of sales and marketing teams. The company's gross margin improved to 60% in Q4 from 42% in the prior year.
Covalon Technologies (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has scheduled the release of its Q4 and year end Fiscal 2024 financial results for Tuesday, January 7, 2025, before markets open. The company will host a conference call and webcast at 8:30am ET on the same day to discuss the results.
Participants can join via webcast or dial in through various numbers: North American Toll-Free (1-800-549-8228), Toronto Local (289-819-1520), or New York Local (646-564-2877) using Conference ID: 30029. A Q&A session will be available for participants, and a recording will be accessible on Covalon's website under the Investors tab.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) announces its participation in the 2024 ANCC National Magnet Conference in New Orleans from October 30 to November 1, 2024. The company will showcase its vascular access solutions at Booth 562, featuring products like VALGuard®, IV Clear®, CovaClear® IV, and SurgiClear®. These innovations include antimicrobial dressings and line guards designed to protect IV sites and improve patient comfort. The conference provides an opportunity for Covalon to connect with nursing professionals and demonstrate their commitment to compassionate patient care through innovative medical technology.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) announces its participation in the 2024 Association for Vascular Access (AVA) Annual Scientific Meeting from September 28 to 30 in Colorado. The company will showcase its compassionate vascular access solutions at booth #523, including a new range of CovaClear® IV Vascular Access Dressings.
Covalon's patented products on display include:
- VALGuard® - a transparent line guard
- SurgiClear® - a dual antimicrobial clear silicone adhesive dressing
- IV Clear® - a dual antimicrobial clear IV securement dressing
- CovaClear® IV - a soft silicone adhesive clear IV dressing
CEO Brent Ashton emphasizes the company's commitment to enhancing patient comfort and improving vascular access clinical care. Attendees can book appointments with Covalon representatives to learn more about their innovative solutions.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) has announced the successful redemption of warrants from its 2019 private placement. Company directors exercised 852,700 warrants, generating approximately $1.7 million CAD, while long-term shareholders exercised 1,875,800 warrants, bringing in about $3.8 million CAD. This brings Covalon's net cash position to approximately $16.0 million CAD.
CEO Brent Ashton expressed satisfaction with the confidence shown by insiders and long-term shareholders in Covalon's future value. The warrants, originally set to expire on September 18, 2024, were issued as part of a private placement in September 2019. Following this exercise, Covalon now has 27,398,077 common shares outstanding, with insiders beneficially owning and controlling 14,194,323 shares, representing about 51.8% of the company's outstanding shares.
Covalon Technologies (TSXV:COV, OTCQX:CVALF), an advanced medical technologies company, will be presenting at the Planet MicroCap Showcase: VANCOUVER 2024 in association with Small Cap Discoveries on Thursday, September 26, 2024, at 10:00 AM PST. Brent Ashton, CEO of Covalon, will host the presentation and answer questions.
The live presentation can be accessed via webcast at https://www.webcaster4.com/Webcast/Page/3056/510941. One-on-one meetings will be conducted in person at the Fairmont Waterfront Vancouver. If unable to attend live, the presentation will be available on the conference event platform under the 'Agenda' tab at https://planetmicrocapshowcase.com/agenda.
Covalon Technologies (TSXV: COV; OTCQX: CVALF) reported strong Q3 fiscal 2024 results, with significant year-on-year growth. Key highlights include:
- Q3 revenue of $9.2 million, up 47% year-on-year
- Q3 gross profit of $5.4 million, up 51% year-on-year
- Q3 EBITDA of $1.7 million and adjusted EBITDA of $2.4 million
- Earnings per share (EPS) of $0.06
The company's performance was driven by expansion in US hospitals and stronger demand for its collagen dressing. Gross margin improved to 59%, while operating expenses decreased due to restructuring efforts. The company's CEO, Brent Ashton, emphasized that these results demonstrate progress on key priorities and the success of foundational work to strengthen Covalon.
Covalon Technologies (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, has announced it will release its Q3 Fiscal 2024 financial results on Wednesday, August 21, 2024, before markets open. The company will hold a conference call and webcast to discuss these results on the same day at 8:30am ET.
Participants can join the webcast or dial in to the conference call using the provided links and numbers. The call will include a Q&A session where participants can ask questions to Company management. A recording of the call will be available on Covalon's website under the Investors tab. Financial statements and MD&A can be accessed on SEDAR PLUS and the company's website.